Clinical Research Findings
Medifast announced clinical research findings demonstrating that their program retains 98% of lean mass, reduces visceral fat by 14%, and improves body composition while losing weight.
Strong Financial Position
Medifast maintains a strong balance sheet with $173.5 million in cash, cash equivalents, and investments, and no interest-bearing debt.
New Product Line Announcement
A new product line using metabolic synchronization science and next-generation ingredients for metabolic enhancement is expected to launch next year.
Initial Positive Response to Premier+ Program
The Premier+ pricing and auto ship program has shown an uptick in baseline client retention beyond the first month.